Rita Mukhtar, MD

Title(s)Associate Professor, Surgery
SchoolSchool of Medicine
Address550 16th Street, #6311
San Francisco CA 94158
PronounsShe/Her/Hers
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California, San FranciscoM.D.2006 Medicine
    University of California, San Francisco, CA2018Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse overview
    Dr. Rita Mukhtar specializes in breast surgery and general surgery for urgent conditions. For her patients with breast cancer, she offers expertise in total skin-sparing mastectomies, breast conservation, wire localization surgery (used to show the location of tissue requiring biopsy) and sentinel lymph node biopsy (used to see if cancer has spread).

    Dr. Mukhtar's research program focuses on invasive lobular carcinoma, the second most common type of breast cancer. This work is funded by the American Cancer Society and the National Cancer Institute. She teaches medical students and residents, and serves as an Associate Program Director for the UCSF General Surgery Residency.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. 410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ. Laboratory Investigation. 2025 Mar 1; 105(3):102637. Ye YJ, Goldhammer GN, Vohra VP, Park PC, Rodas RC, Moasser MM, Abe AS, Alvarado AM, Ewing EC, Goodwin GK, Mukhtar MR, Wong WJ, Esserman EL, Balassanian BR, Rosenbluth RJ. .
      View in: Publisher Site   Mentions:
    2. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 Feb 13. Boughey JC, Yu H, Switalla K, Velle L, Lopes A, Wallace AM, Lancaster RB, Reyna CR, Tuttle TM, Jaskowiak N, Tchou J, Rao R, Lee MC, Naik AM, Golshan M, Arciero CA, Sauder CAM, Matsen CB, Yau C, Esserman L, Mukhtar RA, I-SPY2 Locoregional Working Group. PMID: 39946078.
      View in: PubMed   Mentions:    Fields:    
    3. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. NPJ Breast Cancer. 2025 Feb 13; 11(1):14. Mukhtar RA, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, Boughey JC, Goetz MP, Hoskin T, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Provenzano E, Sammut SJ, Thomas JS, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, J van 't Veer L, Cameron D, Esserman LJ, Fraser Symmans W. PMID: 39948079; PMCID: PMC11825822.
      View in: PubMed   Mentions:
    4. Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study. Tomography. 2024 Nov 20; 10(11):1832-1845. Li W, Le NN, Nadkarni R, Onishi N, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Mukhtar RA, Gennatas ED, Kornak J, Magbanua MJM, Van't Veer LJ, LeStage B, Esserman LJ, Hylton NM. PMID: 39590943; PMCID: PMC11598075.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study. Am J Surg. 2025 Mar; 241:116073. Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Alvarado M, Julian BQ, Ewing C, Wong J, Rose J, Esserman L, Foster R, Mukhtar RA. PMID: 39571369.
      View in: PubMed   Mentions:    Fields:    
    6. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy. Breast Cancer Res Treat. 2025 Jan; 209(1):147-159. Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. PMID: 39305392; PMCID: PMC11785630.
      View in: PubMed   Mentions:    Fields:    
    7. Reply to: "Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)". Breast Cancer Res Treat. 2024 Oct; 207(3):669-670. Kaur M, Rothschild HT, Mukhtar RA. PMID: 39134816.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Variation in surgical treatment by body mass index in patients with invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2024 Dec; 208(3):569-575. Falade IO, Switalla KM, Baxter ME, Quirarte A, Record H, Rothschild HT, Clelland EN, Mukhtar RA. PMID: 39127971; PMCID: PMC11522173.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022. Journal of Clinical Oncology. 2024 Aug 10; 42(23_suppl):1-1. Thomas TA, Wolf WD, Balassanian BR, Chen CY, Ye YJ, Vohra VP, Gulbahce GE, Borowsky BA, Brown Swigart BL, Hirst HG, Venters VS, Nanda NR, Shatsky SR, D'Agostino DR, Mukhtar MR, Hatcher HS, Yau YC, DeMichele DA, van 't Veer vL, Esserman EL. .
      View in: Publisher Site   Mentions:
    10. Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer. Ann Surg Oncol. 2024 Nov; 31(12):8093-8101. Tchou J, Gottipati S, Goldbach M, Baxter M, Venters S, Balassanian R, Vohra P, Gonzalves D, Ahmad Z, Nayak A, Boughey JC, Mukhtar RA, Chen YY. PMID: 39117925; PMCID: PMC11467097.
      View in: PubMed   Mentions:    Fields:    
    11. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ. NPJ Breast Cancer. 2024 Aug 04; 10(1):71. Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A. PMID: 39098868; PMCID: PMC11298531.
      View in: PubMed   Mentions:
    12. ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial. Ann Surg Oncol. 2024 Oct; 31(11):7260-7261. Switalla KM, Boughey JC, Mukhtar RA. PMID: 39048899.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. ASO Author Reflections: Detecting Local Recurrence After Primary Treatment for Invasive Lobular Carcinoma of the Breast. Ann Surg Oncol. 2024 Oct; 31(11):7323-7324. Clelland EN, Mukhtar RA. PMID: 39034367.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. International survey on invasive lobular breast cancer identifies priority research questions. NPJ Breast Cancer. 2024 Jul 20; 10(1):61. Oesterreich S, Pate L, Lee AV, Chen F, Jankowitz RC, Mukhtar R, Metzger O, Sikora MJ, Li CI, Sotiriou C, Shah OS, Koorman T, Ulaner G, Reis-Filho JS, Davidson NM, Van Baelen K, Hutcheson L, Freeney S, Migyanka F, Turner C, Derksen P, Bear T, Desmedt C. PMID: 39033157; PMCID: PMC11271268.
      View in: PubMed   Mentions: 1  
    15. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7249-7259. Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA. PMID: 38995451; PMCID: PMC11452431.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7420-7428. Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Group. PMID: 38980586.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery. Ann Surg Oncol. 2024 Oct; 31(11):7315-7322. Clelland EN, Quirarte A, Rothschild HT, Kaur M, Mujir F, Record H, Wong JM, Mukhtar RA. PMID: 38954091; PMCID: PMC11452458.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    18. The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes. Surgical Oncology Insight. 2024 Jun 1; 1(2):100059. Baskin BA, Huppert HL, Kelil KT, Singer SL, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    19. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):506-506. Cobain CE, Pusztai PL, Graham GC, Whitworth WP, Beitsch BP, Osborne OC, Layeequr Rahman LR, Johnson JN, Brufsky BA, Mahtani MR, Gadi GV, Hoskins HK, Linden LH, Mukhtar MR, Esserman EL, Haan HJ, Quinn QK, Menicucci MA, Audeh AM, O'Shaughnessy OJ. .
      View in: Publisher Site   Mentions:
    20. Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):594-594. Leon-Ferre LR, Dimitroff DK, Yau YC, Giridhar GK, Mukhtar MR, Hirst HG, Hylton HN, Symmans SW, Goetz GM, Esserman EL, Boughey BJ. .
      View in: Publisher Site   Mentions:
    21. Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):582-582. Thomas TA, Wolf WD, Balassanian BR, Chen CY, Ye YJ, Vohra VP, Gulbahce GE, Borowsky BA, Brown Swigart BL, Hirst HG, Venters VS, Nanda NR, Shatsky SR, D'Agostino DR, Mukhtar MR, Hatcher HS, Yau YC, DeMichele DA, van 't Veer vL, Esserman EL. .
      View in: Publisher Site   Mentions:
    22. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC). Journal of Clinical Oncology. 2024 May 29; 42(16_suppl):601-601. Chien CA, Mukhtar MR, Giridhar GK, Olopade OO, Kalinsky KK, Vaklavas VC, Elias EA, Wei WM, Goetz GM, van 't Veer vL, Alkhafaji AS, Rugo RH, Chen CN, Symmans SW, Borowsky BA, Brown Swigart BL, Onishi ON, Yee YD, Hylton HN, Esserman EL. .
      View in: Publisher Site   Mentions:
    23. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment. Semin Oncol. 2024 Jun-Aug; 51(3-4):106-122. Corso G, Fusco N, Guerini-Rocco E, Leonardi MC, Criscitiello C, Zagami P, Nicolò E, Mazzarol G, La Vecchia C, Pesapane F, Zanzottera C, Tarantino P, Petitto S, Bianchi B, Massari G, Boato A, Sibilio A, Polizzi A, Curigliano G, De Scalzi AM, Lauria F, Bonanni B, Marabelli M, Rotili A, Nicosia L, Albini A, Calvello M, Mukhtar RA, Robson ME, Sacchini V, Rennert G, Galimberti V, Veronesi P, Magnoni F. PMID: 38897820.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. ASO Author Reflections: The Oncologic Safety of Immediate Oncoplastic Approaches in Invasive Lobular Carcinoma. Ann Surg Oncol. 2024 Oct; 31(11):7418-7419. Falade I, Mukhtar RA. PMID: 38735901.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma. Ann Surg Oncol. 2024 Oct; 31(11):7409-7417. Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Wong J, Foster R, Mukhtar RA. PMID: 38713388; PMCID: PMC11452432.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study. Cancer Research. 2024 May 2; 84(9_Supplement):po4-02-03-po4-02-03. Mukhtar MR, Yau YC, Wolf WD, Brufsky BA, Linden LH, Hunter HN, Mahtani MR, Sivapiragasam SA, Feinstein FT, Yan YF, Grady GI, McAuliffe MP, Tsai TM, O'Shaughnessy OJ, Mavromatis MB, Davis DS, Haan HJ, Audeh AW, Samraj SL. .
      View in: Publisher Site   Mentions:
    27. Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance. Cancer Research. 2024 May 2; 84(9_Supplement):po5-26-07-po5-26-07. Hutcheson HL, Axelrod AJ, Cushing CT, Fitzwater FC, Jeselsohn JR, Joergensen JG, Karsten KM, Kimm KM, Kruse KM, Langdon LT, Levine LJ, Mitchell-Daniels MM, Mukhtar MR, Neilsen NB, Paluch-Shimon PS, Pross PT. .
      View in: Publisher Site   Mentions:
    28. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. NPJ Breast Cancer. 2024 Feb 26; 10(1):17. Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA. PMID: 38409268; PMCID: PMC10897340.
      View in: PubMed   Mentions:
    29. Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy. Cancer Research. 2024 Feb 1; 84(3_Supplement_1):a059-a059. Goldhammer GN, Warhadpande WS, Beld BL, Maldonado Rodas MC, Lam LA, Bui BT, Abe AS, Alvarado AM, Ewing EC, Goodwin GK, Mukhtar MR, Wong WJ, Swigart SL, Hirst HG, Schwartz SC, van't Veer vL, Esserman EL, Chien CJ, Rosenbluth RJ. .
      View in: Publisher Site   Mentions:
    30. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma. Adv Radiat Oncol. 2024 May; 9(5):101448. Chen JJ, Zhu I, Patel A, Krings G, Chen YY, Yuen F, Mukhtar RA, Melisko M, Singer L, Park CC, Prionas ND. PMID: 38550370; PMCID: PMC10965428.
      View in: PubMed   Mentions:
    31. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk. Cell Stem Cell. 2024 01 04; 31(1):106-126.e13. Northey JJ, Hayward MK, Yui Y, Stashko C, Kai F, Mouw JK, Thakar D, Lakins JN, Ironside AJ, Samson S, Mukhtar RA, Hwang ES, Weaver VM. PMID: 38181747; PMCID: PMC11050720.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    32. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes. Ann Surg Oncol. 2024 Jan; 31(1):398-399. Parmeshwar N, Dugan CL, Barnes LL, Cheng JK, Patterson AK, Miller A, Mukhtar R, Piper M. PMID: 37840115.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants. Breast Cancer Res Treat. 2024 Feb; 204(1):171-179. Schwartz CJ, Khorsandi N, Blanco A, Mukhtar RA, Chen YY, Krings G. PMID: 38091153; PMCID: PMC10806021.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    34. ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment. Ann Surg Oncol. 2023 11; 30(12):7152. Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M, Mukhtar RA. PMID: 37626250.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer. NPJ Breast Cancer. 2023 Oct 26; 9(1):88. Record H, Clelland E, Rothschild HT, Kaur M, Chien AJ, Melisko M, Rugo HS, Mujir F, Huppert L, Mukhtar RA. PMID: 37884561; PMCID: PMC10603127.
      View in: PubMed   Mentions: 1  
    36. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns". Ann Surg Oncol. 2024 01; 31(1):401-402. Mukhtar RA, Huppert L, Ramalingam K. PMID: 37851197.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB). Breast Cancer Res Treat. 2024 Jan; 203(2):245-256. Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA. PMID: 37833450; PMCID: PMC10787876.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study. Annals of Oncology. 2023 Oct 1; 34:s325-s326. Gottipati GS, Earl EH, Yau YC, Cameron CD, Abraham AJ, Hayward HL, Reyal RF, Osdoit OM, Sonke SG, Wesseling WJ, Boughey BJ, Goetz GM, DeMichele DA, Pusztai PL, Sharma SP, Jimenez JM, Cobo CS, Del Monte-Millan DM, Symmans SF, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    39. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM. J Clin Transl Sci. 2023; 7(1):e202. Rothschild HT, Jo Chien A, Jankowitz RC, Magbanua MJ, Mouabbi JA, Shatsky RA, Levine J, Mukhtar RA. PMID: 37830005; PMCID: PMC10565189.
      View in: PubMed   Mentions: 1  
    40. Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes. Ann Surg Oncol. 2023 Dec; 30(13):8428-8435. Parmeshwar N, Dugan CL, Barnes LL, Cheng JK, Patterson AK, Miller A, Mukhtar R, Piper M. PMID: 37700172.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma. Ann Surg Oncol. 2023 Nov; 30(12):7137-7138. Ramalingam K, Mukhtar R. PMID: 37561346.
      View in: PubMed   Mentions:    Fields:    
    42. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment. Ann Surg Oncol. 2023 Nov; 30(12):7099-7106. Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M, Mukhtar RA. PMID: 37561345; PMCID: PMC10562340.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes. Cancer Epidemiol Biomarkers Prev. 2023 08 01; 32(8):1107-1113. Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA. PMID: 37257200; PMCID: PMC10390860.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes. Breast Cancer Res Treat. 2023 Nov; 202(2):367-375. Clelland EN, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Benz CC, Mukhtar RA. PMID: 37500962; PMCID: PMC10505592.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database. Res Sq. 2023 Jul 19. Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA. PMID: 37503233; PMCID: PMC10371122.
      View in: PubMed   Mentions:
    46. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy. Ann Surg Oncol. 2023 Oct; 30(10):5999-6006. Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, Alvarado M, Ewing C, Mukhtar RA. PMID: 37464134; PMCID: PMC10495501.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast. Ann Surg Oncol. 2023 10; 30(10):6008-6009. Rothschild HT, Mukhtar RA. PMID: 37460737.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Editorial: Contrast mammography-a promising tool for the pre-operative evaluation of lobular breast cancer. Eur J Radiol. 2023 09; 166:110982. Jochelson MS, Mukhtar RA. PMID: 37523873.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial. Ann Surg Oncol. 2023 Oct; 30(11):6401-6410. Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA. PMID: 37380911.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    50. Metabolic Positron Emission Tomography in Breast Cancer. PET Clin. 2023 Oct; 18(4):473-485. Cecil K, Huppert L, Mukhtar R, Dibble EH, O'Brien SR, Ulaner GA, Lawhn-Heath C. PMID: 37369614.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    51. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial. Ann Surg. 2023 09 01; 278(3):320-327. Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, ISPY-2 Locoregional Working Group. PMID: 37325931.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    52. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply. JAMA Surg. 2023 06 01; 158(6):675. Mukhtar RA, Yau C, Esserman LJ. PMID: 36811873.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Time to Surgery in Breast Cancer-Is Faster Always Better? JAMA Surg. 2023 05 01; 158(5):492-493. Mukhtar RA, Esserman LJ. PMID: 36857037.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study. Journal of Clinical and Translational Science. 2023 Apr 24; 7(s1):121-122. Clelland CE, Gonzalez-Vargas GJ, Palilla PS, Koliwad KS, Greenwood GH, Schwartz SC, Benz BC, Alba AD, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    55. 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression. Journal of Clinical and Translational Science. 2023 Apr 24; 7(s1):14-14. Rothschild RH, Chien CA, Jankowitz JR, Magbanua MM, Mouabbi MJ, Shatsky SR, Levine LJ, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    56. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. Breast Cancer Res Treat. 2023 Jun; 199(2):349-354. Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Mukhtar RA. PMID: 37017812; PMCID: PMC10175465.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    57. Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. Cancer Research. 2023 Mar 1; 83(5_Supplement):her2-14-her2-14. Rothschild RH, Clelland CE, Patterson PA, Molina-Vega MJ, Kaur KM, Abel AM, Symmans SW, Schwartz SC, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    58. Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. Cancer Research. 2023 Mar 1; 83(5_Supplement):p2-03-16-p2-03-16. Clelland CE, Rothschild RH, Patterson PA, Molina-Vega MJ, Kaur KM, Abel AM, Symmans SW, Chien CJ, Schwartz SC, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    59. Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP). Cancer Research. 2023 Mar 1; 83(5_Supplement):p3-09-01-p3-09-01. Rosenbluth RJ, Schwartz SC, Bui BT, Warhadpande WS, Phadatare PP, Eini ES, Bruck BM, Molina-Vega MJ, Pullakhandam PK, Schindler SN, Brown Swigart BL, Yau YC, Hirst HG, Mukhtar MR, Giridhar GK, Olopade OO, Kalinsky KK, Ewing EC, Wong WJ, Alvarado AM, Veer VL, Esserman EL, Chien CJ. .
      View in: Publisher Site   Mentions:
    60. Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival. Cancer Research. 2023 Mar 1; 83(5_Supplement):p6-08-09-p6-08-09. Kaur KM, Patterson PA, Molina-Vega MJ, Rothschild RH, Clelland CE, Abel AM, Esserman EL, Olopade OO, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    61. Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas. Cancer Research. 2023 Mar 1; 83(5_Supplement):p6-05-10-p6-05-10. Oesterreich OS, Pate PL, LEE LA, Jankowitz JR, Derksen DP, Mukhtar MR, Metzger MO, Sikora SM, Li LC, Sotiriou SC, Ulaner UG, Reis-Filho RJ, Davidson DN, Van Baelen VK, Hutcheson HL, Freeney FS, Migyanka MF, Turner TC, Bear BT, Desmedt DC. .
      View in: Publisher Site   Mentions:
    62. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. Mod Pathol. 2023 05; 36(5):100125. Schwartz CJ, Ruiz J, Bean GR, Sirohi D, Joseph NM, Hosfield EM, Jacobs TW, Mukhtar RA, Chen YY, Krings G. PMID: 36870308.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes. Plast Reconstr Surg Glob Open. 2023 Jan; 11(1):e4767. Barnes LL, Foster R, Mukhtar RA, Esserman LJ, Ewing C, Alvarado M, Wong J, Piper M. PMID: 36776594; PMCID: PMC9911193.
      View in: PubMed   Mentions:
    64. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort. Cancer Res Commun. 2022 12; 2(12):1579-1589. Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ. PMID: 36970720; PMCID: PMC10035518.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    65. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education. Am J Surg. 2023 03; 225(3):591-592. Conroy PC, Mohamedaly S, Karimzada M, Brian R, Im C, Hernandez S, Roman S, Hirose K, Mukhtar R, Kirkwood K, O'Sullivan P, Alseidi A. PMID: 36443105.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study. Ann Surg Oncol. 2022 Nov; 29(12):7750. Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. PMID: 35798896.
      View in: PubMed   Mentions:    Fields:    
    67. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041. Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA. PMID: 36069821; PMCID: PMC9453630.
      View in: PubMed   Mentions: 7     Fields:    
    68. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival. Journal of the American College of Surgeons. 2022 Oct 17; 235(5):s34-s34. Baskin BA, Patterson PA, Blanco BA, Mak MJ, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    69. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography. Surg Oncol Clin N Am. 2022 10; 31(4):569-579. Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, Jones EF, Mukhtar RA. PMID: 36243494; PMCID: PMC10277169.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency. Global Surgical Education - Journal of the Association for Surgical Education. 2022 Aug 25; 1(1):36. Bongiovanni BT, Lancaster LE, Decker DH, Mukhtar MR, Schwab SM, Broering BJ, O’Sullivan OP, Hirose HK, Wick WE. .
      View in: Publisher Site   Mentions:
    71. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study. Ann Surg Oncol. 2022 Nov; 29(12):7739-7747. Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. PMID: 35810223; PMCID: PMC9550696.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    72. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype. Ann Surg Oncol. 2022 11; 29(12):7748-7749. Abel MK, Mukhtar RA. PMID: 35798894; PMCID: PMC9550674.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression. Cancer Research. 2022 Jun 15; 82(12_Supplement):lb021-lb021. Northey NJ, Yui YY, Hayward HM, Stashko SC, Kai KF, Mouw MJ, Thakar TD, Lakins LJ, Ironside IA, Samson SS, Mukhtar MR, Hwang HE, Weaver WV. .
      View in: Publisher Site   Mentions:
    74. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):504-504. Huppert HL, Rugo RH, Pusztai PL, Mukhtar MR, Chien CA, Yau YC, Wolf WD, Berry BD, van 't Veer vL, Yee YD, DeMichele DA, Esserman EL. .
      View in: Publisher Site   Mentions:
    75. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply. JAMA Oncol. 2022 04 01; 8(4):1. Mukhtar R, Symmans WF, Esserman LJ. PMID: 35201273.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership. J Surg Res. 2022 09; 277:A25-A35. Greenberg AL, Sullins VF, Donahue TR, Sundaram VM, Saldinger PF, Divino CM, Anton NE, Stefanidis D, Reilly LM, Egan RJ, Beals CKJ, Riall TS, Duh QY, Mukhtar RA, Hirose K, Lebares CC. PMID: 35307162.
      View in: PubMed   Mentions:    Fields:    
    77. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer. Cancer Research. 2022 Feb 15; 82(4_Supplement):ot1-10-02-ot1-10-02. Chien CA, Kalinsky KK, Molina-Vega MJ, Mukhtar MR, Giridhar GK, Olopade OO, Basu BA, Asare AS, Henderson HP, Hirst HG, Lu LR, Jones JE, Hylton HN, Brown-Swigart BL, van 't Veer vL, Yee YD, Mayer MI, Esserman EL. .
      View in: Publisher Site   Mentions:
    78. Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma. Cancer Research. 2022 Feb 15; 82(4_Supplement):p3-02-01-p3-02-01. Jones JE, Hathi HD, Konovalova KN, Molina-Vega MJ, Newitt ND, Lawhn-Heath LC, Ray RK, Joe JB, Heditsian HD, Brain BS, Chien CA, Esserman EL, Hylton HN, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    79. Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers. Cancer Research. 2022 Feb 15; 82(4_Supplement):p3-02-02-p3-02-02. Jones JE, Hathi HD, Molina-Vega MJ, Newitt ND, Lawhn-Heath LC, Ray RK, Joe JB, Heditsian HD, Brain BS, Mukhtar MR, Chien CA, Rugo RH, Esserman EL, Hylton HN. .
      View in: Publisher Site   Mentions:
    80. Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer. Cancer Research. 2022 Feb 15; 82(4_Supplement):p2-02-02-p2-02-02. Alkhafaji AS, Wolf WD, Magbanua MM, Van 't Veer VL, Park PJ, Esserman EL, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    81. Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL. Cancer Research. 2022 Feb 15; 82(4_Supplement):p3-03-07-p3-03-07. Christofferson CA, Price PE, Mukhtar MR, Basu BA, Esserman EL, Chien CA. .
      View in: Publisher Site   Mentions:
    82. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. NPJ Breast Cancer. 2021 Dec 21; 7(1):156. Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA. PMID: 34934058; PMCID: PMC8692497.
      View in: PubMed   Mentions: 9  
    83. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast Cancer Res Treat. 2022 Jan; 191(2):451-458. Rothschild HT, Abel MK, Patterson A, Goodman K, Shui A, van Baelen K, Desmedt C, Benz C, Mukhtar RA. PMID: 34817747; PMCID: PMC8763723.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    84. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR. British Journal of Surgery. 2021 Nov 24; 108(Supplement_8). Dhanani DN, Olavarria OO, Lee LK, Young YC, Primus PF, Mukhtar MR, Holihan HJ, Liang LM, Harris HH. .
      View in: Publisher Site   Mentions:
    85. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? NPJ Breast Cancer. 2021 Oct 25; 7(1):139. Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA. PMID: 34697300; PMCID: PMC8547221.
      View in: PubMed   Mentions: 1  
    86. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. PMID: 34611148; PMCID: PMC8492731.
      View in: PubMed   Mentions: 13  
    87. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief. NPJ Breast Cancer. 2021 Sep 17; 7(1):123. Khoury AL, Keane H, Varghese F, Hosseini A, Mukhtar R, Eder SE, Weinstein PR, Esserman LJ. PMID: 34535677; PMCID: PMC8448876.
      View in: PubMed   Mentions: 6  
    88. Correction to: Applications of 3D printing in breast cancer management. 3D Print Med. 2021 Jul 07; 7(1):19. Galstyan A, Bunker MJ, Lobo F, Sims R, Inziello J, Stubbs J, Mukhtar R, Kelil T. PMID: 34232424; PMCID: PMC8261959.
      View in: PubMed   Mentions: 2  
    89. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies. Am J Surg. 2022 04; 223(4):699-704. Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA. PMID: 34148670.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    90. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):1092-1092. Abel AM, Melisko MM, Rugo RH, Chien CA, Diaz DI, Levine LJ, Griffin GA, McGuire MJ, Esserman EL, Borno BH, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    91. Early onset, multiple, bilateral fibroadenomas of the breast: a case report. BMC Womens Health. 2021 04 21; 21(1):170. Im CJ, Miller A, Balassanian R, Mukhtar RA. PMID: 33882939; PMCID: PMC8061223.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    92. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions. Current Breast Cancer Reports. 2021 Apr 12; 1-7. Mukhtar MR, Chien CA. .
      View in: Publisher Site   Mentions:
    93. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial. Ann Surg. 2021 04 01; 273(4):648-655. Harris HW, Primus F, Young C, Carter JT, Lin M, Mukhtar RA, Yeh B, Allen IE, Freise C, Kim E, Sbitany H, Young DM, Hansen S. PMID: 33443907.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansPHPublic Health
    94. Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors. Breast Cancer Res Treat. 2021 Aug; 188(3):739-747. Tang A, Cohan CM, Hansen KS, Beattie G, Greenwood HI, Mukhtar RA. PMID: 33772708.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    95. ASO Author Reflections: Changes in Primary Treatment Strategy for Invasive Lobular Carcinoma Highlight the Need for Better Predictors of Therapy Response. Ann Surg Oncol. 2021 10; 28(11):5878-5879. Mukhtar RA, Boughey JC. PMID: 33704606.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    96. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB). Ann Surg Oncol. 2021 Oct; 28(11):5867-5877. Mukhtar RA, Hoskin TL, Habermann EB, Day CN, Boughey JC. PMID: 33687613; PMCID: PMC8460506.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    97. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma. NPJ Breast Cancer. 2021 Mar 05; 7(1):25. Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA. PMID: 33674614; PMCID: PMC7935955.
      View in: PubMed   Mentions: 9  
    98. Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy. Cancer Research. 2021 Feb 15; 81(4_Supplement):pd6-08-pd6-08. Tran TG, Jones JE, Li LW, Fahrner-Scott FK, Newitt ND, Joe JB, Esserman EL, Hylton HN, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    99. Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS. Cancer Research. 2021 Feb 15; 81(4_Supplement):pd5-01-pd5-01. Greenwood GH, Freimanis FR, Brabham BC, Mukhtar MR, Hirst HG, Kim KP, Liang LA, Esserman EL, Hylton HN, Basu BA. .
      View in: Publisher Site   Mentions:
    100. Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up. Cancer Research. 2021 Feb 15; 81(4_Supplement):ps1-03-ps1-03. Brabham BC, Mukhtar MR, Liang LA, Kim KP, Hirst HG, Basu BA, Greenwood GH, Freimanis FR, Borowsky BA, Hwang HS, Baehner BR, Krings KG, Hylton HN, Esserman EL. .
      View in: Publisher Site   Mentions:
    101. Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast. Cancer Research. 2021 Feb 15; 81(4_Supplement):ps17-05-ps17-05. Rothschild RH, Esserman EL, Benz BC, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    102. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability. Breast. 2021 Apr; 56:61-69. Scheepens JCC, Veer LV', Esserman L, Belkora J, Mukhtar RA. PMID: 33621798; PMCID: PMC7907889.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    103. Applications of 3D printing in breast cancer management. 3D Print Med. 2021 Feb 09; 7(1):6. Galstyan A, Bunker MJ, Lobo F, Sims R, Inziello J, Stubbs J, Mukhtar R, Kelil T. PMID: 33559793; PMCID: PMC7871648.
      View in: PubMed   Mentions: 9  
    104. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines. Am J Transplant. 2021 09; 21(9):3014-3020. Hansen KS, Ghersin H, Piper M, Tavakol M, Lee B, Esserman LJ, Roberts JP, Freise C, Ascher NL, Mukhtar RA. PMID: 33421310.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives. Breast J. 2021 04; 27(4):406-408. Mukhtar RA, Brabham CE, Guo R, Abel MK, Wong J, Ewing C, Esserman LJ, Alvarado M. PMID: 33486856.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    106. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. J Clin Invest. 2020 11 02; 130(11):5721-5737. Northey JJ, Barrett AS, Acerbi I, Hayward MK, Talamantes S, Dean IS, Mouw JK, Ponik SM, Lakins JN, Huang PJ, Wu J, Shi Q, Samson S, Keely PJ, Mukhtar RA, Liphardt JT, Shepherd JA, Hwang ES, Chen YY, Hansen KC, Littlepage LE, Weaver VM. PMID: 32721948; PMCID: PMC7598051.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimals
    107. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience. Ann Surg Oncol. 2021 May; 28(5):2555-2560. Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA. PMID: 33025355.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    108. 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials. European Journal of Cancer. 2020 Oct 1; 138:s69-s70. Abel AM, Diaz DI, Levine LJ, Pate PL, Viggiano VE, Melisko MM, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    109. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2020 Oct; 183(3):661-667. Abel MK, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Park C, Mukhtar RA. PMID: 32696313.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater. Am J Surg. 2021 01; 221(1):32-36. Abel MK, Brabham CE, Guo R, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Mukhtar RA. PMID: 32622509; PMCID: PMC7736057.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    111. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. Cancers (Basel). 2020 Jun 09; 12(6). Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM. PMID: 32527022; PMCID: PMC7352259.
      View in: PubMed   Mentions: 7  
    112. 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast. Journal of Clinical and Translational Science. 2020 Jun 1; 4(s1):38-38. Abel AM, Wong WJ, Alvarado AM, Ewing EC, Esserman EL, Park PC, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    113. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e12604-e12604. Guo GR, Brabham BC, Fahrner-Scott FK, Abel AM, Wong WJ, Alvarado AM, Esserman EL, Ewing EC, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    114. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. Breast Cancer Res Treat. 2020 May; 181(1):23-29. Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H. PMID: 32240457.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    115. Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB). Cancer Research. 2020 Feb 15; 80(4_Supplement):p4-13-01-p4-13-01. Mukhtar MR, Hoskin HT, Habermann HE, Boughey BJ. .
      View in: Publisher Site   Mentions:
    116. Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study. Cancer Research. 2020 Feb 15; 80(4_Supplement):p5-08-05-p5-08-05. O'Keefe OT, Yau YC, Jeong JE, Iaconetti IE, Kim KP, Griffin GA, McGuire MJ, Mukhtar MR, Esserman EL, Harismendy HO, Hirst HG. .
      View in: Publisher Site   Mentions:
    117. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast. Cancer Research. 2020 Feb 15; 80(4_Supplement):pd9-08-pd9-08. Fahrner-Scott FK, Wong WJ, Piper PM, Ewing EC, Alvarado AM, Esserman EL, Hylton HN, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    118. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy. Cancer Research. 2020 Feb 15; 80(4_Supplement):p6-16-06-p6-16-06. Kim KP, Greenwood GH, Freimanis FR, Hirst HG, Fischer-Colbrie FM, Gibbs GJ, Hylton HN, Yau YC, Hwang HE, Esserman EL, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    119. Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL. Cancer Research. 2020 Feb 15; 80(4_Supplement):p3-08-16-p3-08-16. Osdoit OM, Yau YC, Symmans SW, Boughey BJ, Asare AS, Balassanian BR, Carter CJ, Chen CY, Cole CK, Khazai KL, Klein KM, Kokh KD, Krings KG, Sahoo SS, Ahrendt AG, Chiba CA, Ewing EC, Godellas GC, Jaskowiak JN, Killelea KB, Krontiras KH, Lancaster LR, Lang LJ, Lee LM, Naik NA, Rao RR, Tchou TJ, Tierney TS, Tousimis TE, Tuttle TT, Wallace WA, Parker PB, Esserman EL, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    120. Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry. Cancer Research. 2020 Feb 15; 80(4_Supplement):ot3-09-01-ot3-09-01. Wei WJ, Kim KP, Ewing EC, Wong WJ, Esserman EL, Alvarado AM, Olusanya OA, Stewart SS, Tydon TA, Daroui DP, Kuo KJ, Park PH, Lane LK, Jeong JE, Brown BK, Hosseini HA, Parker PB, Blair BS, Investigators IA, Baehner BF, Harismendy HO, Petruse PA, Thompson TC, Chang CH, Borowsky BA, Yau YC, Hirst HG, Bold BR, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    121. Pragmatic Trials and Approaches to Transforming Care. . 2020 Jan 1; 59-76. Stock SP, Mukhtar MR, Ghersin GH, Stover Fiscalini SA, Esserman EL. .
      View in: Publisher Site   Mentions:
    122. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study. J Am Coll Surg. 2020 01; 230(1):53-63.e1. Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS. PMID: 31672679; PMCID: PMC6934897.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    123. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast. NPJ Breast Cancer. 2019; 5:29. Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, Mukhtar RA. PMID: 31508489; PMCID: PMC6731236.
      View in: PubMed   Mentions: 17  
    124. Editorial: Applying Margin Consensus Guidelines to Invasive Lobular Carcinoma of the Breast. Ann Surg Oncol. 2019 Nov; 26(12):3798-3799. Mukhtar RA. PMID: 31485821.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    125. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment. AJR Am J Roentgenol. 2019 10; 213(4):953-957. Greenwood HI, Wong JM, Mukhtar RA, Alvarado MD, Price ER. PMID: 31166765.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    126. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12. Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. PMID: 31016232; PMCID: PMC6467896.
      View in: PubMed   Mentions: 12  
    127. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications. Plast Reconstr Surg Glob Open. 2019 Apr; 7(4):e2188. Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR. PMID: 31321184; PMCID: PMC6554181.
      View in: PubMed   Mentions: 5  
    128. Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction. Plastic & Reconstructive Surgery Global Open. 2019 Apr 1; 7(4 Suppl):82-83. Holland HM, Lentz LR, Gomez-Sanchez GC, Rothman RJ, Wong WJ, Mukhtar MR, Sbitany SH. .
      View in: Publisher Site   Mentions:
    129. Changes in mammographic density following bariatric surgery. Surg Obes Relat Dis. 2019 Jun; 15(6):964-968. Hosseini A, Khoury AL, Varghese F, Carter J, Wong JM, Mukhtar RA. PMID: 31076368.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    130. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. Poster Session Abstracts. 2019 Feb 15; p6-01-04-p6-01-04. Jones JE, Ray RK, Mukhtar MR, Li LW, Franc FB, Esserman EL, Joe JB, Pampaloni PM, Hylton HN. .
      View in: Publisher Site   Mentions:
    131. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast. Poster Session Abstracts. 2019 Feb 15; p1-15-15-p1-15-15. Fahrner-Scott FK, Wong WJ, Piper PM, Ewing EC, Alvarado AM, Esserman EL, Hylton HN, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    132. Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain. Poster Session Abstracts. 2019 Feb 15; p4-11-01-p4-11-01. Keane KH, Khoury KA, Hosseini HA, Varghese VF, Mukhtar MR, Eder ES, Wong WJ, Esserman EL. .
      View in: Publisher Site   Mentions:
    133. Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL. Cancer Research. 2019 Feb 15; 79(4_Supplement):pd7-06-pd7-06. Zhu ZZ, Yau YC, Chien CA, Haddad HT, Esserman EL, van't Veer vL, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    134. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2019; 5:2. Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators. PMID: 30675512; PMCID: PMC6315027.
      View in: PubMed   Mentions: 1  
    135. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents. JAMA Surg. 2018 12 01; 153(12):1090-1096. Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, Esserman L, Mukhtar R, Finlayson E. PMID: 30167636; PMCID: PMC6433538.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    136. ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients. Ann Surg Oncol. 2018 12; 25(Suppl 3):622-623. Mukhtar RA. PMID: 30151561.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    137. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2018; 4:26. Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators. PMID: 30131975; PMCID: PMC6098077.
      View in: PubMed   Mentions: 7  
    138. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients. Ann Surg Oncol. 2018 Oct; 25(11):3165-3170. Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M, Sbitany H, Alvarado M, Foster R, Ewing C, Esserman L. PMID: 30054826.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    139. 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast. European Journal of Cancer. 2018 Apr 1; 92:s132. Mamounas MM, Wong WJ, Fahrner-Scott FK, Chen CY, Krings KG, Ewing EC, Esserman EL, Alvarado AM, Rugo RH, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    140. Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast. Poster Session Abstracts. 2018 Feb 15; p2-12-16-p2-12-16. Wong WJ, Piper PM, Ewing EC, Alvarado AM, Esserman EL, Sbitany SH, Foster FR, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    141. Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density. Poster Session Abstracts. 2018 Feb 15; p5-12-04-p5-12-04. Hosseini HA, Khoury KA, Carter CJ, Wong WJ, Alvarado AM, Ewing EC, Esserman EL, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    142. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention. Poster Session Abstracts. 2018 Feb 15; p5-22-22-p5-22-22. Hosseini HA, Esserman EL, Wallace WA, Au AA, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    143. Breast tumor location in BRCA mutation carriers and implications for prevention. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):e13048-e13048. Hosseini HA, Esserman EL, Wallace WA, Khoury KA, Au AA, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    144. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017 01; 161(1):17-28. Campbell MJ, Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L. PMID: 27785654; PMCID: PMC5225037.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    145. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer. Am J Transplant. 2017 01; 17(1):292-295. Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ. PMID: 27501470.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    146. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015 Jul 16; 3(7):607-13. Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. PMID: 26244152; PMCID: PMC4517335.
      View in: PubMed   Mentions: 11  
    147. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care. J Natl Compr Canc Netw. 2015 Jun; 13(6):737-43. Mukhtar RA, Wong JM, Esserman LJ. PMID: 26085389.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    148. Abstract PD1-5: Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ. Poster Discussion Abstracts. 2015 May 1; pd1-5-pd1-5. Campbell CM, Mukhtar MR, Obi-Okoye OE, Han HB, Tandon TV, Zheng ZS, Zhu ZZ, Endicott EM, Wicha WM, Lindstrom LL, Au AA, Baehner BF, Gray GJ, Esserman EL. .
      View in: Publisher Site   Mentions:
    149. Abstract 165: Suppressed immunity and macrophages characterize high risk high grade DCIS. Tumor Biology. 2014 Oct 1; 165-165. Campbell CM, Mukhtar MR, Obi-Okoye OE, Han HB, Tandon TV, Zheng ZS, Zhu ZZ, Endicott EM, Wicha WM, Lindstrom LL, Au AA, Baehner BF, Gray GJ, Esserman EL. .
      View in: Publisher Site   Mentions:
    150. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ. PMID: 24205370; PMCID: PMC3812150.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    151. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30. Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ. PMID: 23780381; PMCID: PMC3824937.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    152. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators. PMID: 22961065; PMCID: PMC5702179.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    153. Biology of breast cancer in Nigerian women: a pilot study. Ann Afr Med. 2012 Jul-Sep; 11(3):169-75. Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ. PMID: 22684136.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    154. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012 Nov; 19(12):3979-86. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Campbell MJ, Esserman LJ. PMID: 22622474.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    155. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial. Poster Session Abstracts. 2011 Dec 15; p1-06-10-p1-06-10. Mukhtar MR, Lips LE, Wesseling WJ, Livasy LC, Yau YC, Berry BD, van't Veer vL, Carey CL, Esserman EL, Rodenhuis RS, Hwang HE. .
      View in: Publisher Site   Mentions:
    156. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial. Poster Discussion Abstracts. 2011 Dec 15; pd02-05-pd02-05. Mukhtar MR, Hylton HN, Rosen RM. .
      View in: Publisher Site   Mentions:
    157. P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment. Poster Session Abstracts. 2011 Dec 15; p4-09-19-p4-09-19. Mukhtar MR, Wolf WD, Tandon TV, Zhu ZJ, Lenburg LM, van't vV, Campbell CM. .
      View in: Publisher Site   Mentions:
    158. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44. Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Campbell MJ, Esserman LJ. PMID: 21717106.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    159. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness. Journal of Clinical Oncology. 2011 May 20; 29(15_suppl):1043-1043. Mukhtar MR, Moore MA, Tandon TV, Nseyo NO, Au AA, Baehner BF, Adisa AC, Eleweke EN, Olopade OO, Moore MD, Campbell CM, Esserman EL. .
      View in: Publisher Site   Mentions:
    160. Benign Thoracic Disease in the Elderly. Cardiothoracic Surgery in the Elderly. 2011 Jan 1; 517-526. Mukhtar MR, Theodore TP. .
      View in: Publisher Site   Mentions:
    161. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100. Mukhtar RA, Nseyo O, Campbell MJ, Campbell MJ, Esserman LJ. PMID: 21171924.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    162. Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy. Poster Session Abstracts. 2010 Dec 15; p2-09-11-p2-09-11. Mukhtar MR, Hwang HE, Livasy LC, Esserman EL. .
      View in: Publisher Site   Mentions:
    163. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences. Journal of Clinical Oncology. 2010 May 20; 28(15_suppl):1110-1110. Mukhtar MR, Moore MA, Nseyo NO, Au AA, Baehner BF, Moore MD, Campbell CM, Esserman EL. .
      View in: Publisher Site   Mentions:
    164. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence. J Pediatr Surg. 2009 Dec; 44(12):e31-3. Mukhtar RA, Baskin LS, Stock PG, Lee H. PMID: 20006002.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    165. Bacteriologic features of surgical site infections following breast surgery. Am J Surg. 2009 Oct; 198(4):529-31. Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, Chiu C, Hwang ES. PMID: 19800462.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    166. Benign thoracic disease in the elderly. Thorac Surg Clin. 2009 Aug; 19(3):313-9. Mukhtar RA, Theodore PR. PMID: 20066943.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    167. Variation in annual volume at a university hospital does not predict mortality for pancreatic resections. HPB Surg. 2008; 2008:190914. Mukhtar RA, Kattan OM, Harris HW. PMID: 19259261; PMCID: PMC2648113.
      View in: PubMed   Mentions: 2     Fields:    
    168. Image of the month--quiz case. Traumatic intramuscular cyst of the duodenum. Arch Surg. 2005 Oct; 140(10):1005-6. Spitzer AL, Mukhtar RA, Harris HW. PMID: 16230553.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    169. Quality-of-life issues in psoriasis. Dermatol Clin. 2004 Oct; 22(4):389-95, viii. Mukhtar R, Choi J, Koo JY. PMID: 15450335.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    Rita's Networks
    Concepts (229)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (102)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-12-gbedcc43d on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.